Share This Page
Suppliers and packagers for LAMICTAL XR
✉ Email this page to a colleague
LAMICTAL XR
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Glaxosmithkline Llc | LAMICTAL XR | lamotrigine | TABLET, EXTENDED RELEASE;ORAL | 022115 | NDA | GlaxoSmithKline LLC | 0173-0754-00 | 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0173-0754-00) | 2009-07-06 |
| Glaxosmithkline Llc | LAMICTAL XR | lamotrigine | TABLET, EXTENDED RELEASE;ORAL | 022115 | NDA | GlaxoSmithKline LLC | 0173-0755-00 | 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0173-0755-00) | 2009-07-06 |
| Glaxosmithkline Llc | LAMICTAL XR | lamotrigine | TABLET, EXTENDED RELEASE;ORAL | 022115 | NDA | GlaxoSmithKline LLC | 0173-0756-00 | 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0173-0756-00) | 2009-07-06 |
| Glaxosmithkline Llc | LAMICTAL XR | lamotrigine | TABLET, EXTENDED RELEASE;ORAL | 022115 | NDA | GlaxoSmithKline LLC | 0173-0757-00 | 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0173-0757-00) | 2009-07-06 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: LAMICTAL XR
Introduction
Lamictal XR (lamotrigine extended-release) is a critical anticonvulsant and mood stabilizer primarily used for epilepsy and bipolar disorder management. As a patented and widely prescribed medication, its supply chain is crucial for ensuring consistent access to patients worldwide. Understanding the key suppliers involved in the manufacturing, distribution, and packaging of Lamictal XR provides vital insights into the drug’s availability, supply chain resilience, and potential risks affecting market stability.
Manufacturers of Lamictal XR
Teva Pharmaceutical Industries Ltd.
Teva is one of the largest generic pharmaceutical manufacturers globally and a significant supplier of lamotrigine extended-release formulations, including Lamictal XR. The company holds multiple patents and manufacturing rights for this drug, providing both branded and generic versions.
- Production Facilities: Teva operates manufacturing plants in Israel, Hungary, and the United States, which adhere to stringent Good Manufacturing Practices (GMP).
- Market Role: Teva's global distribution network ensures widespread availability of Lamictal XR, especially in North America and Europe. Their capacity to produce both active pharmaceutical ingredients (APIs) and finished dosage forms helps stabilize supply.
Alvogen
Alvogen is a specialty pharmaceutical company involved in producing generic drugs, including lamotrigine products such as Lamictal XR.
- Manufacturing Sites: Alvogen’s manufacturing facilities span the United States, Europe, and Asia, emphasizing geographic diversification to mitigate supply disruptions.
- Product Portfolio: Besides lamotrigine, Alvogen produces a spectrum of generic medications, optimizing integration within their supply chain for cost-efficient production.
Mylan (Now part of Viatris)
Mylan, merged with Pfizer’s Upjohn division forming Viatris, has historically been a key manufacturer of lamotrigine extended-release formulations.
- Production Capabilities: Mylan’s extensive manufacturing footprint across Europe and North America bolsters supply security for Lamictal XR.
- Regulatory Approvals: Multiple approvals for generics allow Viatris to distribute Lamictal XR broadly, addressing regional market demands.
Glenmark Pharmaceuticals
Glenmark offers generic lamotrigine formulations and has gained regulatory approval for their extended-release versions in various markets.
- Manufacture & Distribution: The company’s manufacturing facilities in India and the US support the global supply chain, especially in emerging markets.
Sun Pharmaceutical Industries Ltd.
Sun Pharma produces generic lamotrigine, including the XR formulations, gaining market access through strategic licensing.
- Manufacturing Presence: Their facilities in India, the US, and other regions contribute to a diversified supply base.
Key Regulatory and Patent Considerations
Patent Landscape
Before the expiration of patent exclusivity, manufacturers like GlaxoSmithKline (GSK) held patent rights on Lamictal XR. Once patents expire, multiple generic manufacturers can produce bioequivalent versions, expanding supply options.
Regulatory Approvals
Manufacturers require approvals from agencies like the FDA (U.S. Food and Drug Administration), EMA (European Medicines Agency), and other national regulators to market Lamictal XR.
- FDA Approvals: Ensures compliance with safety, efficacy, and quality standards.
- Bioequivalence Data: Approvals typically depend on bioequivalence studies comparing generics to the branded formulation.
Supply Chain Dynamics
Active Pharmaceutical Ingredient (API) Suppliers
The supply chain for Lamictal XR begins with the sourcing of lamotrigine APIs, predominantly produced in India, China, and Europe by specialized chemical manufacturers.
Formulation and Manufacturing
API is sent to global manufacturing sites where it is formulated into extended-release tablets, encapsulated, or packaged. Companies like Teva, Mylan, and Alvogen operate vertically integrated operations, controlling the API to finished product transition.
Distribution Channels
Distribution of Lamictal XR involves wholesalers, pharmacies, and hospitals worldwide. The complexity of global logistics underscores the importance of diversified manufacturing sources to prevent shortages.
Supply Risks
- Manufacturing Disruptions: Quality issues, regulatory delays, or facility shutdowns can impede supply.
- Raw Material Shortages: Constraints in API production or shortages in raw materials impact product availability.
- Regulatory Bottlenecks: Changes in approval status or new regional regulations can temporarily restrict distribution.
Major Suppliers and Market Share
While exact market share data remains proprietary, key players like Teva, Mylan (Viatris), Alvogen, Glenmark, and Sun Pharma dominate the supply landscape.
- Teva: Historically the largest supplier, particularly in North America and Europe.
- Viatris: Holds significant market share post-Mylan merger, expanding global supply channels.
- Regional Players: In emerging markets, local manufacturers like Sun Pharma and Glenmark meet regional demand.
Emerging Trends and Future Supply Considerations
Generic Competition and Market Dynamics
The expiration of patent protections has led to increased generic manufacturing, reducing prices and expanding supply. Competition among these suppliers enhances market stability but can also lead to strategic sourcing challenges.
Manufacturing Consolidation
Recent industry consolidations aim to enhance capacity and quality control but may also pose short-term supply risks during transition periods.
Supply Chain Resilience
Manufacturers invest in expanding API production capacities and establishing dual sourcing agreements to mitigate risks of disruption. Strategic stockpiling and regional manufacturing hubs are key strategies to ensure continuity.
Conclusion
The supply landscape for Lamictal XR features a diversified set of global manufacturers, primarily including Teva, Viatris (Mylan), Alvogen, Glenmark, and Sun Pharma. Their combined manufacturing capacities, regulatory adherence, and geographic distribution underpin the consistent availability of this essential drug. Nonetheless, supply chains remain susceptible to disruptions stemming from manufacturing issues, raw material shortages, and regulatory changes. Stakeholders must monitor these factors vigilantly to maintain steady access to Lamictal XR, especially amid market shifts and capacity expansions.
Key Takeaways
- Dominant Manufacturers: Teva, Viatris (Mylan), Alvogen, Glenmark, and Sun Pharma are primary suppliers globally.
- Supply Chain Diversification: Geographic spread of manufacturing facilities enhances resilience but introduces complexity.
- API Sourcing: Dependence on raw material suppliers in China and India emphasizes geopolitical risks.
- Regulatory Landscape: Compliance with global and regional standards is vital for uninterrupted supply.
- Market Trends: Increased generic competition fosters affordability but requires vigilant supply chain management.
FAQs
1. Who are the leading producers of Lamictal XR globally?
Teva, Viatris (formerly Mylan), Alvogen, Glenmark, and Sun Pharma are the primary manufacturers of Lamictal XR, collectively covering a significant portion of the global supply.
2. What factors could disrupt the supply of Lamictal XR?
Disruptions may arise from manufacturing facility issues, shortages of raw materials, regulatory delays, or strategic market shifts among producers.
3. Are there regional differences in the availability of Lamictal XR?
Yes. Availability varies based on regional regulatory approvals, local manufacturing presence, and distribution networks. Developed regions like North America and Europe generally have more stable supplies.
4. How does patent expiration affect supplier competition?
Patents expiring allows multiple generic manufacturers to produce bioequivalent versions, increasing supplier options and potentially improving supply resilience and lowering prices.
5. What strategies are companies adopting to ensure supply chain stability?
Manufacturers are investing in expanding API manufacturing, establishing multiple sourcing agreements, geographic diversification of plants, and maintaining safety stock levels.
References
[1] U.S. FDA Drug Approvals Database.
[2] European Medicines Agency (EMA) Product Approvals.
[3] Industry reports on generic pharmaceutical manufacturing.
[4] Company annual reports and investor presentations.
More… ↓
